Alle verbonden artikelen

The 41st David A. Karnofsky Memorial Award Lecture: Academic research worldwide--quo vadis?

Auteurs : Piccart-Gebhart M
Jaar : 2014
Journal : J. Clin. Oncol.
Volume : 32(4)
Pagina's : 347-54

A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes.

Auteurs : Garaud S, Gu-Trantien C, Lodewyckx JN, Boisson A, De Silva P, Buisseret L, Migliori E, Libin M, Naveaux C, Duvillier H, Willard-Gallo K
Jaar : 2014
Journal : J Vis Exp
Volume : null(94)

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

Auteurs : Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart-Gebhart M, Sotiriou C, Ignatiadis M
Jaar : 2014
Journal : Ann Oncol
Volume : 25(10)
Pagina's : 1959-65

Genomic grade adds prognostic value in invasive lobular carcinoma.

Auteurs : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Jaar : 2013
Journal : Ann Oncol
Volume : 24
Pagina's : 377-384

Luminal breast cancer: from biology to treatment.

Auteurs : Ignatiadis M, Sotiriou C
Jaar : 2013
Journal : Nat Rev Clin Oncol
Volume : 10(9)
Pagina's : 494-506

Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development

Auteurs : Vanderbeeken MC, Aftimos P, Awada A
Jaar : 2013
Journal : Current Breast Cancer Rep
Volume : 5
Pagina's : 31-41

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Auteurs : Goldhirsch A, Gelber Rd, Piccart-Gebhart M, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, Mcfadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J
Jaar : 2013
Journal : Lancet
Volume : 382(9897)
Pagina's : 1021-8

Impressive response to eribulin in endocrine- and chemotherapy resistant metastatic breast cancer

Auteurs : Vanderbeeken MC, de Azambuja E
Jaar : 2013
Journal : Belgian J Medical Oncology
Volume : 7(1)
Pagina's : 27-30

Why your preferred targeted drugs may become unaffordable.

Auteurs : Piccart-Gebhart M
Jaar : 2013
Journal : Cancer Res
Volume : 73(19)
Pagina's : 5849-51

CD4+ follicular helper T cell infiltration predicts breast cancer survival.

Auteurs : Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothé F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart-Gebhart M, Sotiriou C, Willard-Gallo K
Jaar : 2013
Journal : J Clin Invest
Volume : 123(7)
Pagina's : 2873-92

Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer.

Auteurs : Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A
Jaar : 2013
Journal : J. Clin. Oncol.
Volume : 31(20)
Pagina's : 2586-92

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.

Auteurs : Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart-Gebhart M, Sotiriou C
Jaar : 2013
Journal : PLoS One
Volume : 8(1)
Pagina's : e53292

Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles.

Auteurs : Aftimos P, Wiedig M, Langouo Fontsa M, Awada A, Ghanem G, Journe F
Jaar : 2013
Journal : Int J Oncol
Volume : 43(3)
Pagina's : 919-26

Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.

Auteurs : Saghatchian M, Mook S, Pruneri G, Viale G, Glas AM, Guerin S, Cardoso F, Piccart-Gebhart M, Tursz T, Delaloge S, van t Veer L
Jaar : 2013
Journal : Breast
Volume : 22(5)
Pagina's : 682-90

Targeting RANKL in breast cancer: bone metastasis and beyond.

Auteurs : Azim H, Azim HA
Jaar : 2013
Journal : Expert Rev Anticancer Ther
Volume : 13(2)
Pagina's : 195-201

Breast cancer in young women - Special Issue.

Auteurs : Azim HA, Peccatori FA
Jaar : 2013
Journal : J Thorac Dis
Volume : 5(Suppl 1)
Pagina's : S1

Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.

Auteurs : Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart-Gebhart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI
Jaar : 2013
Journal : J. Natl. Cancer Inst.
Volume : 105(9)
Pagina's : 654-63

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.

Auteurs : Azim HA, Michiels S, Zagouri F, Delaloge S, Filipits M, Namer M, Neven P, Symmans WF, Thompson A, André F, Loi S, Swanton C
Jaar : 2013
Journal : Ann Oncol
Volume : 24(3)
Pagina's : 647-54

Multigene assays for late recurrence of breast cancer.

Auteurs : Ignatiadis M
Jaar : 2013
Journal : Lancet Oncol
Volume : 14(11)
Pagina's : 1029-30

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab.

Auteurs : Zabaglo L, Stoss O, Rüschoff J, Zielinski D, Salter J, Arfi M, Bradbury I, Dafni U, Piccart-Gebhart M, Procter M, Dowsett M
Jaar : 2013
Journal : Ann Oncol
Volume : 24(11)
Pagina's : 2761-6